title: Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
abstract: Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). Although B-cell depletion therapy (BCDT) has demonstrated efficacy in SLE with visceral involvement, its usefulness for patients with predominant skin manifestations has not been fully established. In this single-centre, retrospective study 14 consecutive SLE, one CCLE and two SCLE patients with recalcitrant skin involvement were treated with 2 × rituximab 1 g, and 1 × cyclophosphamide 750 mg. Six months after BCDT, nine of 17 (53%) patients were in complete (CR) or partial remission (PR). Relapses occurred in 12 patients (71%) at a mean time of 10 ± 1.8 months after BCDT. A second cycle of BCDT achieved a more sustained remission in seven of nine patients (78%) lasting for a mean time of 18.4 ± 2.7 months. Minor adverse events were experienced by three patients. Mean follow-up was 30 months. Our own results and the literature review demonstrate that BCDT based on rituximab is well tolerated and may be effective for cutaneous lesions of lupus erythematosus. Randomized controlled trials are necessary to further evaluate the value of BCDT for this group of patients.
authors.affiliation: Centre for Rheumatology Research, University College London, London, UK. silke.hofmann@helios-kliniken.de
authors.forename: S C
authors.initials: SC
authors.lastname: Hofmann
authors.forename: M J
authors.initials: MJ
authors.lastname: Leandro
authors.forename: S D
authors.initials: SD
authors.lastname: Morris
authors.forename: D A
authors.initials: DA
authors.lastname: Isenberg
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology*; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab
keywords: Cutaneous lupus; discoid lupus; subacute lupus erythematosus; systemic lupus erythematosus
references.citation: Clin Rheumatol. 2009 Jun;28(6):745-6
references.pmid: 19343472
references.citation: J Am Acad Dermatol. 2011 Dec;65(6):e179-93
references.pmid: 20739095
references.citation: J Dtsch Dermatol Ges. 2008 May;6(5):366-73
references.pmid: 18201220
references.citation: Clin Dermatol. 2006 Sep-Oct;24(5):348-62
references.pmid: 16966017
references.citation: Drugs. 2010 Mar 26;70(5):529-40
references.pmid: 20297867
references.citation: Arthritis Rheum. 2010 Aug;62(8):2458-66
references.pmid: 20506527
references.citation: Rheumatology (Oxford). 2006 Jul;45(7):915-6
references.pmid: 16690759
references.citation: Lupus. 2011 Jun;20(7):709-16
references.pmid: 21478286
references.citation: Australas J Dermatol. 2009 Aug;50(3):202-6
references.pmid: 19659984
references.citation: Arthritis Rheum. 1982 Nov;25(11):1271-7
references.pmid: 7138600
references.citation: J Invest Dermatol. 1986 Mar;86(3):235-9
references.pmid: 3489051
references.citation: Actas Dermosifiliogr. 2012 Jul-Aug;103(6):555-7
references.pmid: 22482740
references.citation: J Clin Aesthet Dermatol. 2009 May;2(5):29-37
references.pmid: 20729962
references.citation: Arthritis Rheum. 2009 Apr 15;61(4):482-7
references.pmid: 19333973
references.citation: Dermatology. 2008;216(3):257-9
references.pmid: 18182821
references.citation: Bull NYU Hosp Jt Dis. 2007;65(3):200-4
references.pmid: 17922670
references.citation: Ann Rheum Dis. 2011 Jan;70(1):54-9
references.pmid: 20833737
references.citation: Nat Rev Immunol. 2009 Jan;9(1):15-27
references.pmid: 19079135
references.citation: Br J Dermatol. 2010 Jul;163(1):83-92
references.pmid: 20394621
references.citation: J Clin Rheumatol. 2010 Oct;16(7):345
references.pmid: 20859218
references.citation: Autoimmun Rev. 2004 Aug;3(6):423-53
references.pmid: 15351310
references.citation: Lupus. 2009 Aug;18(9):767-76
references.pmid: 19578100
references.citation: Br J Dermatol. 2012 Mar;166(3):616-23
references.pmid: 21999437
references.citation: Arthritis Rheum. 2012 Aug;64(8):2677-86
references.pmid: 22553077
references.citation: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD002954
references.pmid: 19821298
references.citation: Arthritis Rheum. 2005 Oct;52(10):3168-74
references.pmid: 16200620
references.citation: Lupus. 2010 Aug;19(9):1020-8
references.pmid: 20693195
references.citation: J Clin Rheumatol. 2011 Apr;17(3):142-4
references.pmid: 21441817
references.citation: Rheumatology (Oxford). 2007 Apr;46(4):626-30
references.pmid: 17189244
references.citation: Arthritis Rheum. 2010 Jan;62(1):222-33
references.pmid: 20039413